{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T18:43:10Z","timestamp":1785436990022,"version":"3.56.0"},"reference-count":58,"publisher":"American Association for Cancer Research (AACR)","issue":"11","funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["T32-AI07405"],"award-info":[{"award-number":["T32-AI07405"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA271537"],"award-info":[{"award-number":["R01CA271537"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA207913"],"award-info":[{"award-number":["R01CA207913"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30CA046934"],"award-info":[{"award-number":["P30CA046934"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000738","name":"U.S. Department of Veterans Affairs","doi-asserted-by":"publisher","award":["BX004935"],"award-info":[{"award-number":["BX004935"]}],"id":[{"id":"10.13039\/100000738","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>The recent FDA approval of the first T-cell receptor\u2013engineered (TCR) T-cell cancer therapy has solidified the treatment as a viable therapeutic strategy. However, only a fraction of patients who received this treatment achieved substantial and long-lasting responses, highlighting the need to understand the molecular underpinnings of these responses and develop more effective strategies to improve this therapy. Previous research has demonstrated that the activation of myeloid differentiation primary response 88 (MyD88) signaling in tumor-specific T cells functions as a robust costimulatory signaling pathway that promotes effective antitumor T-cell responses. In this study, we developed a strategy for improving TCR T-cell therapies by creating a synthetic TCR in which the intracellular domain of CD3\u03b6 and a modified MyD88 are appended to the \u03b2-chain of a tumor-reactive TCR. The \u03b2:CD3\u03b6:MyD88 TCR activated MyD88 signaling in a tumor antigen\/TCR-specific manner, and \u03b2:CD3\u03b6:MyD88 TCR T cells exhibited enhanced functionality and a reduced propensity to become exhausted. Furthermore, MyD88 signaling promoted T-cell persistence and expansion in vitro. In vivo, tumor-infiltrating \u03b2:CD3\u03b6:MyD88 TCR T cells skewed the immunosuppressive tumor microenvironment toward a less immunosuppressive state. Finally, \u03b2:CD3\u03b6:MyD88 TCR T cells substantially delayed tumor growth kinetics in a melanoma model. These findings introduce an approach for improving TCR-dependent T-cell responses by directly appending signaling domains to the full-length TCR and exemplify the utility of activating MyD88 signaling in tumor-specific T cells.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>A chimeric \u03b2:CD3\u03b6:MyD88 TCR reduces exhaustion and improves antitumor T-cell responses, overcoming the limited efficacy of current TCR-engineered T-cell cancer therapies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/0008-5472.can-25-0777","type":"journal-article","created":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T19:31:41Z","timestamp":1773257501000},"page":"2688-2702","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Engineering T Cells with a Tumor-Reactive Chimeric T-cell Receptor Reduces Exhaustion and Promotes Persistence to Elicit Enhanced Antitumor Responses"],"prefix":"10.1158","volume":"86","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3988-0749","authenticated-orcid":false,"given":"Joey C.","family":"Magno","sequence":"first","affiliation":[{"name":"University of Colorado School of Medicine 1 Department of Medicine, Division of Medical Oncology, , Aurora, Colorado."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0927-4249","authenticated-orcid":false,"given":"Jitao","family":"Guo","sequence":"additional","affiliation":[{"name":"University of Colorado School of Medicine 1 Department of Medicine, Division of Medical Oncology, , Aurora, Colorado."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6783-2344","authenticated-orcid":false,"given":"Spencer C.","family":"Hall","sequence":"additional","affiliation":[{"name":"University of Colorado Anschutz Medical Campus 2 Section of Hematology, Oncology and Bone Marrow Transplantation, Department of Pediatrics, , Aurora, Colorado."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-3658-0463","authenticated-orcid":false,"given":"Jing","family":"Liu","sequence":"additional","affiliation":[{"name":"University of Colorado School of Medicine 1 Department of Medicine, Division of Medical Oncology, , Aurora, Colorado."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6238-7720","authenticated-orcid":false,"given":"Gabriella K.","family":"Albert","sequence":"additional","affiliation":[{"name":"University of Colorado School of Medicine 1 Department of Medicine, Division of Medical Oncology, , Aurora, Colorado."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-7640-3662","authenticated-orcid":false,"given":"Jake D.","family":"Carter","sequence":"additional","affiliation":[{"name":"University of Colorado School of Medicine 1 Department of Medicine, Division of Medical Oncology, , Aurora, Colorado."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-7208-2868","authenticated-orcid":false,"given":"Andres S.","family":"Davalos","sequence":"additional","affiliation":[{"name":"University of Colorado School of Medicine 1 Department of Medicine, Division of Medical Oncology, , Aurora, Colorado."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5928-5384","authenticated-orcid":false,"given":"Phoebe","family":"Cao","sequence":"additional","affiliation":[{"name":"University of Colorado School of Medicine 1 Department of Medicine, Division of Medical Oncology, , Aurora, Colorado."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2147-8789","authenticated-orcid":false,"given":"Amandip","family":"Bangar","sequence":"additional","affiliation":[{"name":"University of Colorado School of Medicine 1 Department of Medicine, Division of Medical Oncology, , Aurora, Colorado."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9687-4233","authenticated-orcid":false,"given":"Zoe","family":"Drigot","sequence":"additional","affiliation":[{"name":"University of Colorado School of Medicine 1 Department of Medicine, Division of Medical Oncology, , Aurora, Colorado."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5688-8182","authenticated-orcid":false,"given":"Hannah","family":"Hudson","sequence":"additional","affiliation":[{"name":"University of Colorado School of Medicine 1 Department of Medicine, Division of Medical Oncology, , Aurora, Colorado."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-5046-0565","authenticated-orcid":false,"given":"Taylor","family":"Geluck","sequence":"additional","affiliation":[{"name":"University of Colorado School of Medicine 1 Department of Medicine, Division of Medical Oncology, , Aurora, Colorado."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-2256-6715","authenticated-orcid":false,"given":"Wendy K.","family":"Nevala","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02qp3tb03","id-type":"ROR","asserted-by":"publisher"}],"name":"Mayo Clinic 3 Department of Oncology, , Rochester, Minnesota."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9238-4325","authenticated-orcid":false,"given":"Svetomir N.","family":"Markovic","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02qp3tb03","id-type":"ROR","asserted-by":"publisher"}],"name":"Mayo Clinic 3 Department of Oncology, , Rochester, Minnesota."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5080-497X","authenticated-orcid":false,"given":"Breelyn A.","family":"Wilky","sequence":"additional","affiliation":[{"name":"University of Colorado School of Medicine 1 Department of Medicine, Division of Medical Oncology, , Aurora, Colorado."},{"name":"4University of Colorado Comprehensive Cancer Center, Aurora, Colorado."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9738-4167","authenticated-orcid":false,"given":"Eduardo","family":"Davila","sequence":"additional","affiliation":[{"name":"University of Colorado School of Medicine 1 Department of Medicine, Division of Medical Oncology, , Aurora, Colorado."},{"name":"4University of Colorado Comprehensive Cancer Center, Aurora, Colorado."},{"name":"5Department of Veteran Affairs Research Service, Rocky Mountain Regional VA Medical Center, Aurora, Colorado."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2026,3,11]]},"reference":[{"key":"2026060103074856300_bib1","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1186\/s12967-024-05703-9","article-title":"TCR-T cell therapy: current development approaches, preclinical evaluation, and perspectives on regulatory challenges","volume":"22","author":"Golikova","year":"2024","journal-title":"J Transl Med"},{"key":"2026060103074856300_bib2","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1126\/science.1129003","article-title":"Cancer regression in patients after transfer of genetically engineered lymphocytes","volume":"314","author":"Morgan","year":"2006","journal-title":"Science"},{"key":"2026060103074856300_bib3","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1016\/S0140-6736(24)00319-2","article-title":"Afamitresgene autoleucel for advanced synovial sarcoma and myxoid round cell liposarcoma (SPEARHEAD-1): an international, open-label, phase 2 trial","volume":"403","author":"D\u2019Angelo","year":"2024","journal-title":"Lancet"},{"key":"2026060103074856300_bib4","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1038\/nature14468","article-title":"T-cell exhaustion, co-stimulation and clinical outcome in autoimmunity and infection","volume":"523","author":"McKinney","year":"2015","journal-title":"Nature"},{"key":"2026060103074856300_bib5","doi-asserted-by":"crossref","first-page":"e1792","DOI":"10.1038\/cddis.2015.162","article-title":"T-cell exhaustion in the tumor microenvironment","volume":"6","author":"Jiang","year":"2015","journal-title":"Cell Death Dis"},{"key":"2026060103074856300_bib6","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1038\/s43018-024-00744-x","article-title":"Synthetic dual co-stimulation increases the potency of HIT and TCR-Targeted cell therapies","volume":"5","author":"Dobrin","year":"2024","journal-title":"Nat Cancer"},{"key":"2026060103074856300_bib7","doi-asserted-by":"crossref","first-page":"2903","DOI":"10.1002\/ijc.28320","article-title":"Enhanced antitumor activity mediated by human 4-1BB-engineered T cells","volume":"133","author":"Daniel-Meshulam","year":"2013","journal-title":"Int J Cancer"},{"key":"2026060103074856300_bib8","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1158\/2326-6066.CIR-21-0307","article-title":"A costimulatory CAR improves TCR-based cancer immunotherapy","volume":"10","author":"Omer","year":"2022","journal-title":"Cancer Immunol Res"},{"key":"2026060103074856300_bib9","doi-asserted-by":"crossref","first-page":"1617773","DOI":"10.3389\/fimmu.2025.1617773","article-title":"Leveraging innate immune signals in CD8+ T cells to boost antitumor immunity","volume":"16","author":"Albert","year":"2025","journal-title":"Front Immunol"},{"key":"2026060103074856300_bib10","doi-asserted-by":"crossref","first-page":"e20191166","DOI":"10.1084\/jem.20191166","article-title":"A Fas-4-1BB fusion protein converts a death to a pro-survival signal and enhances T cell therapy","volume":"217","author":"Oda","year":"2020","journal-title":"J Exp Med"},{"key":"2026060103074856300_bib11","doi-asserted-by":"crossref","first-page":"314","DOI":"10.3389\/fnmol.2019.00314","article-title":"Inflammatory role of TLR-MyD88 signaling in multiple sclerosis","volume":"12","author":"Zheng","year":"2019","journal-title":"Front Mol Neurosci"},{"key":"2026060103074856300_bib12","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1002\/eji.200636181","article-title":"TLR2 engagement on CD8 T cells lowers the threshold for optimal antigen-induced T cell activation","volume":"36","author":"Cottalorda","year":"2006","journal-title":"Eur J Immunol"},{"key":"2026060103074856300_bib13","doi-asserted-by":"crossref","first-page":"2704","DOI":"10.1182\/blood-2007-07-104141","article-title":"TLR9 engagement on CD4 T lymphocytes represses gamma-radiation-induced apoptosis through activation of checkpoint kinase response elements","volume":"111","author":"Zheng","year":"2008","journal-title":"Blood"},{"key":"2026060103074856300_bib14","doi-asserted-by":"crossref","first-page":"7442","DOI":"10.1158\/0008-5472.CAN-10-0247","article-title":"Amplifying TLR-MyD88 signals within tumor-specific T cells enhances antitumor activity to suboptimal levels of weakly immunogenic tumor antigens","volume":"70","author":"Geng","year":"2010","journal-title":"Cancer Res"},{"key":"2026060103074856300_bib15","doi-asserted-by":"crossref","first-page":"7049","DOI":"10.1158\/0008-5472.CAN-17-0653","article-title":"A synthetic CD8alpha:MyD88 coreceptor enhances CD8","volume":"77","author":"Kaczanowska","year":"2017","journal-title":"Cancer Res"},{"key":"2026060103074856300_bib16","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1182\/blood-2011-02-337360","article-title":"A transgene-encoded cell surface polypeptide for selection, in vivo tracking, and ablation of engineered cells","volume":"118","author":"Wang","year":"2011","journal-title":"Blood"},{"key":"2026060103074856300_bib17","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1038\/s41392-021-00823-w","article-title":"T cell receptor (TCR) signaling in health and disease","volume":"6","author":"Shah","year":"2021","journal-title":"Signal Transduct Target Ther"},{"key":"2026060103074856300_bib18","doi-asserted-by":"crossref","first-page":"3530","DOI":"10.1182\/blood-2003-05-1524","article-title":"Redirection of antileukemic reactivity of peripheral T lymphocytes using gene transfer of minor histocompatibility antigen HA-2-specific T-cell receptor complexes expressing a conserved alpha joining region","volume":"102","author":"Heemskerk","year":"2003","journal-title":"Blood"},{"key":"2026060103074856300_bib19","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1093\/jb\/mvm234","article-title":"IRAK-4-dependent degradation of IRAK-1 is a negative feedback signal for TLR-mediated NF-kappaB activation","volume":"143","author":"Kubo-Murai","year":"2008","journal-title":"J Biochem"},{"key":"2026060103074856300_bib20","doi-asserted-by":"crossref","first-page":"3990","DOI":"10.1128\/MCB.00722-12","article-title":"beta-TrCP-mediated IRAK1 degradation releases TAK1-TRAF6 from the membrane to the cytosol for TAK1-dependent NF-kappaB activation","volume":"32","author":"Cui","year":"2012","journal-title":"Mol Cell Biol"},{"key":"2026060103074856300_bib21","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/j.molcel.2014.08.006","article-title":"IRAK4 dimerization and trans-autophosphorylation are induced by myddosome assembly","volume":"55","author":"Ferrao","year":"2014","journal-title":"Mol Cell"},{"key":"2026060103074856300_bib22","doi-asserted-by":"crossref","first-page":"901277","DOI":"10.3389\/fimmu.2022.901277","article-title":"GM-CSF: a double-edged sword in cancer immunotherapy","volume":"13","author":"Kumar","year":"2022","journal-title":"Front Immunol"},{"key":"2026060103074856300_bib23","doi-asserted-by":"crossref","first-page":"4501","DOI":"10.1182\/blood-2010-10-310425","article-title":"Coexpression of Tim-3 and PD-1 identifies a CD8+ T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia","volume":"117","author":"Zhou","year":"2011","journal-title":"Blood"},{"key":"2026060103074856300_bib24","doi-asserted-by":"crossref","first-page":"455","DOI":"10.3389\/fimmu.2013.00455","article-title":"Inhibitory receptor expression depends more dominantly on differentiation and activation than \u201cexhaustion\u201d of human CD8 T cells","volume":"4","author":"Legat","year":"2013","journal-title":"Front Immunol"},{"key":"2026060103074856300_bib25","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s13073-020-00722-9","article-title":"Single-cell transcriptome analysis reveals TOX as a promoting factor for T cell exhaustion and a predictor for anti-PD-1 responses in human cancer","volume":"12","author":"Kim","year":"2020","journal-title":"Genome Med"},{"key":"2026060103074856300_bib26","doi-asserted-by":"crossref","first-page":"e002591","DOI":"10.1136\/jitc-2021-002591","article-title":"Mechanisms of regulatory T cell infiltration in tumors: implications for innovative immune precision therapies","volume":"9","author":"Nishikawa","year":"2021","journal-title":"J Immunother Cancer"},{"key":"2026060103074856300_bib27","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1016\/j.jcmgh.2021.07.006","article-title":"Myeloid cell mediated immune suppression in pancreatic cancer","volume":"12","author":"Kemp","year":"2021","journal-title":"Cell Mol Gastroenterol Hepatol"},{"key":"2026060103074856300_bib28","doi-asserted-by":"crossref","first-page":"2808","DOI":"10.4049\/jimmunol.176.5.2808","article-title":"Regulated compartmentalization of programmed cell death-1 discriminates CD4+CD25+ resting regulatory T cells from activated T cells","volume":"176","author":"Raimondi","year":"2006","journal-title":"J Immunol"},{"key":"2026060103074856300_bib29","doi-asserted-by":"crossref","first-page":"5488","DOI":"10.1182\/blood-2008-10-187179","article-title":"Maturation of mouse NK cells is a 4-stage developmental program","volume":"113","author":"Chiossone","year":"2009","journal-title":"Blood"},{"key":"2026060103074856300_bib30","doi-asserted-by":"crossref","first-page":"6269","DOI":"10.4049\/jimmunol.1202533","article-title":"Markers of nonselective and specific NK cell activation","volume":"190","author":"Fogel","year":"2013","journal-title":"J Immunol"},{"key":"2026060103074856300_bib31","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1111\/j.1365-2567.2011.03446.x","article-title":"CD11b and CD27 reflect distinct population and functional specialization in human natural killer cells","volume":"133","author":"Fu","year":"2011","journal-title":"Immunology"},{"key":"2026060103074856300_bib32","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1038\/s12276-021-00576-0","article-title":"Function of gammadelta T cells in tumor immunology and their application to cancer therapy","volume":"53","author":"Park","year":"2021","journal-title":"Exp Mol Med"},{"key":"2026060103074856300_bib33","doi-asserted-by":"crossref","first-page":"30412","DOI":"10.1074\/jbc.272.48.30412","article-title":"Interaction of NF-kappaB and NFAT with the interferon-gamma promoter","volume":"272","author":"Sica","year":"1997","journal-title":"J Biol Chem"},{"key":"2026060103074856300_bib34","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.immuni.2010.07.004","article-title":"Modular utilization of distal cis-regulatory elements controls Ifng gene expression in T cells activated by distinct stimuli","volume":"33","author":"Balasubramani","year":"2010","journal-title":"Immunity"},{"key":"2026060103074856300_bib35","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1111\/j.1600-065X.2009.00771.x","article-title":"Costimulatory and coinhibitory receptors in anti-tumor immunity","volume":"229","author":"Driessens","year":"2009","journal-title":"Immunol Rev"},{"key":"2026060103074856300_bib36","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3389\/fcell.2020.00017","article-title":"T cell dysfunction and exhaustion in cancer","volume":"8","author":"Zhang","year":"2020","journal-title":"Front Cell Dev Biol"},{"key":"2026060103074856300_bib37","doi-asserted-by":"crossref","first-page":"113898","DOI":"10.1016\/j.celrep.2024.113898","article-title":"NR4a1\/2 deletion promotes accumulation of TCF1+ stem-like precursors of exhausted CD8+ T cells in the tumor microenvironment","volume":"43","author":"Srirat","year":"2024","journal-title":"Cell Rep"},{"key":"2026060103074856300_bib38","doi-asserted-by":"crossref","first-page":"eabn7336","DOI":"10.1126\/scitranslmed.abn7336","article-title":"BLIMP1 and NR4A3 transcription factors reciprocally regulate antitumor CAR T cell stemness and exhaustion","volume":"14","author":"Jung","year":"2022","journal-title":"Sci Transl Med"},{"key":"2026060103074856300_bib39","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/s12276-021-00568-0","article-title":"Transcriptional regulatory network for the establishment of CD8+ T cell exhaustion","volume":"53","author":"Seo","year":"2021","journal-title":"Exp Mol Med"},{"key":"2026060103074856300_bib40","doi-asserted-by":"crossref","first-page":"12410","DOI":"10.1073\/pnas.1905675116","article-title":"TOX and TOX2 transcription factors cooperate with NR4A transcription factors to impose CD8+ T cell exhaustion","volume":"116","author":"Seo","year":"2019","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2026060103074856300_bib41","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.immuni.2015.01.023","article-title":"The importance of cooperation: partnerless NFAT induces T cell exhaustion","volume":"42","author":"Bengsch","year":"2015","journal-title":"Immunity"},{"key":"2026060103074856300_bib42","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.immuni.2015.01.006","article-title":"The transcription factor NFAT promotes exhaustion of activated CD8+ T cells","volume":"42","author":"Martinez","year":"2015","journal-title":"Immunity"},{"key":"2026060103074856300_bib43","doi-asserted-by":"crossref","first-page":"3365","DOI":"10.1172\/JCI80006","article-title":"Tumor-induced myeloid deviation: when myeloid-derived suppressor cells meet tumor-associated macrophages","volume":"125","author":"Ugel","year":"2015","journal-title":"J Clin Invest"},{"key":"2026060103074856300_bib44","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s40364-020-00228-x","article-title":"Roles of IFN-gamma in tumor progression and regression: a review","volume":"8","author":"Jorgovanovic","year":"2020","journal-title":"Biomark Res"},{"key":"2026060103074856300_bib45","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1038\/s41467-023-44391-9","article-title":"FOXP3+ regulatory T cell perturbation mediated by the IFNgamma-STAT1-IFITM3 feedback loop is essential for anti-tumor immunity","volume":"15","author":"Liu","year":"2024","journal-title":"Nat Commun"},{"key":"2026060103074856300_bib46","doi-asserted-by":"crossref","first-page":"e1408750","DOI":"10.1080\/2162402X.2017.1408750","article-title":"Melanoma induced immunosuppression is mediated by hematopoietic dysregulation","volume":"7","author":"Kamran","year":"2018","journal-title":"Oncoimmunology"},{"key":"2026060103074856300_bib47","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/nature12026","article-title":"M-CSF instructs myeloid lineage fate in single haematopoietic stem cells","volume":"497","author":"Mossadegh-Keller","year":"2013","journal-title":"Nature"},{"key":"2026060103074856300_bib48","doi-asserted-by":"crossref","first-page":"1358750","DOI":"10.3389\/fonc.2024.1358750","article-title":"Macrophage colony-stimulating factor and its role in the tumor microenvironment: novel therapeutic avenues and mechanistic insights","volume":"14","author":"Yi","year":"2024","journal-title":"Front Oncol"},{"key":"2026060103074856300_bib49","doi-asserted-by":"crossref","first-page":"bio062175","DOI":"10.1242\/bio.062175","article-title":"A functional comparison of two transplantable syngeneic mouse models of melanoma: B16F0 and YUMM1.7","volume":"14","author":"Klinke","year":"2025","journal-title":"Biol Open"},{"key":"2026060103074856300_bib50","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.bej.2018.01.010","article-title":"Continuous production process of retroviral vector for adoptive T- cell therapy","volume":"132","author":"Inwood","year":"2018","journal-title":"Biochem Eng J"},{"key":"2026060103074856300_bib51","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/s41591-022-02128-z","article-title":"Autologous T cell therapy for MAGE-A4+ solid cancers in HLA-A*02+ patients: a phase 1 trial","volume":"29","author":"Hong","year":"2023","journal-title":"Nat Med"},{"key":"2026060103074856300_bib52","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1038\/s41586-022-05531-1","article-title":"Non-viral precision T cell receptor replacement for personalized cell therapy","volume":"615","author":"Foy","year":"2023","journal-title":"Nature"},{"key":"2026060103074856300_bib53","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s40164-022-00291-0","article-title":"TCR engineered T cells for solid tumor immunotherapy","volume":"11","author":"Zhang","year":"2022","journal-title":"Exp Hematol Oncol"},{"key":"2026060103074856300_bib54","doi-asserted-by":"crossref","first-page":"43","DOI":"10.2147\/ITT.S202015","article-title":"Cytokine release syndrome: current perspectives","volume":"8","author":"Murthy","year":"2019","journal-title":"Immunotargets Ther"},{"key":"2026060103074856300_bib55","doi-asserted-by":"crossref","first-page":"3423","DOI":"10.1038\/s41467-023-38723-y","article-title":"Neutralizing IFNgamma improves safety without compromising efficacy of CAR-T cell therapy in B-cell malignancies","volume":"14","author":"Manni","year":"2023","journal-title":"Nat Commun"},{"key":"2026060103074856300_bib56","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1182\/blood-2013-03-490565","article-title":"Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma","volume":"122","author":"Linette","year":"2013","journal-title":"Blood"},{"key":"2026060103074856300_bib57","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/j.ymthe.2017.01.011","article-title":"Inducible Caspase-9 selectively modulates the toxicities of CD19-Specific chimeric antigen receptor-modified T cells","volume":"25","author":"Diaconu","year":"2017","journal-title":"Mol Ther"},{"key":"2026060103074856300_bib58","doi-asserted-by":"crossref","first-page":"eadg7123","DOI":"10.1126\/scitranslmed.adg7123","article-title":"Preclinical studies show that Co-STARs combine the advantages of chimeric antigen and T cell receptors for the treatment of tumors with low antigen densities","volume":"16","author":"Mog","year":"2024","journal-title":"Sci Transl Med"}],"container-title":["Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/doi\/10.1158\/0008-5472.CAN-25-0777\/3747014\/can-25-0777.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/86\/11\/2688\/3795795\/can-25-0777.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/86\/11\/2688\/3795795\/can-25-0777.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T07:08:00Z","timestamp":1780297680000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerres\/article\/86\/11\/2688\/785304\/Engineering-T-Cells-with-a-Tumor-Reactive-Chimeric"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,11]]},"references-count":58,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2026,3,11]]},"published-print":{"date-parts":[[2026,6,1]]}},"URL":"https:\/\/doi.org\/10.1158\/0008-5472.can-25-0777","relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/0008-5472.32530415","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.32530406","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.32530418","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.32530400","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.32530412","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.32530403","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.32530394","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.32530409","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.32530397","asserted-by":"object"}],"has-preprint":[{"id-type":"doi","id":"10.1158\/0008-5472.c.8509397","asserted-by":"object"}]},"ISSN":["0008-5472","1538-7445"],"issn-type":[{"value":"0008-5472","type":"print"},{"value":"1538-7445","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,11]]}}}